These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 20421783)
21. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. McCormick SR; Lillemoe TJ; Beneke J; Schrauth J; Reinartz J Am J Clin Pathol; 2002 Jun; 117(6):935-43. PubMed ID: 12047146 [TBL] [Abstract][Full Text] [Related]
22. Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma. Ramieri MT; Murari R; Botti C; Pica E; Zotti G; Alo PL Anticancer Res; 2010 Apr; 30(4):1287-92. PubMed ID: 20530441 [TBL] [Abstract][Full Text] [Related]
23. A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer. Di Palma S; Collins N; Bilous M; Sapino A; Mottolese M; Kapranos N; Schmitt F; Isola J J Clin Pathol; 2008 Jun; 61(6):757-60. PubMed ID: 18326010 [TBL] [Abstract][Full Text] [Related]
24. Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases. Gao FF; Dabbs DJ; Cooper KL; Bhargava R Am J Clin Pathol; 2014 Jan; 141(1):102-10. PubMed ID: 24343743 [TBL] [Abstract][Full Text] [Related]
25. HER2 status in breast cancer determined by IHC and FISH: comparison of the results. Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204 [TBL] [Abstract][Full Text] [Related]
26. HER2 status in gastric cancer: a comparison of two novel in situ hybridization methods (IQ FISH and dual color SISH) and two immunohistochemistry methods (A0485 and HercepTest™). Pala EE; Bayol U; Ozguzer A; Akman O Pathol Res Pract; 2013 Sep; 209(9):548-54. PubMed ID: 23910175 [TBL] [Abstract][Full Text] [Related]
27. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria. Schalper KA; Kumar S; Hui P; Rimm DL; Gershkovich P Arch Pathol Lab Med; 2014 Feb; 138(2):213-9. PubMed ID: 24164555 [TBL] [Abstract][Full Text] [Related]
28. [HER2 gene amplification assay: is CISH an alternative to FISH?]. Denoux Y; Arnould L; Fiche M; Lannes B; Couturier J; Vincent-Salomon A; Penault-Llorca F; Antoine M; Balaton A; Baranzelli MC; Becette V; Bellocq JP; Bibeau F; Ettore F; Fridman V; Gnassia JP; Jacquemier J; MacGrogan G; Mathieu MC; Migeon C; Rigaud C; Roger P; Sigal-Zafrani B; Simony-Lafontaine J; Trassard M; Treilleux I; Verriele V; Voigt JJ; Ann Pathol; 2003 Dec; 23(6):617-22. PubMed ID: 15094603 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of reliability of FISH versus brightfield dual-probe in situ hybridization (BDISH) for frontline assessment of HER2 status in breast cancer samples in a community setting: influence of poor tissue preservation. Schiavon BN; Jasani B; de Brot L; Vassallo J; Damascena A; Cirullo-Neto J; Ivanildo Neves J; Augusto Soares F; Gobbi H; Malagoli Rocha R Am J Surg Pathol; 2012 Oct; 36(10):1489-96. PubMed ID: 22982892 [TBL] [Abstract][Full Text] [Related]
30. [Determination of HER2 by fluorescence in situ hybridization (FISH) in breast cancer. Experience of the Reference Laboratory of Lisbon]. André S; Tomás AR; Fonseca R Acta Med Port; 2005; 18(6):417-22. PubMed ID: 16684481 [TBL] [Abstract][Full Text] [Related]
31. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry. Bilous M; Morey A; Armes J; Cummings M; Francis G Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651 [TBL] [Abstract][Full Text] [Related]
32. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065 [TBL] [Abstract][Full Text] [Related]
33. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573 [TBL] [Abstract][Full Text] [Related]
34. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Moelans CB; de Weger RA; van Diest PJ Breast Cancer Res Treat; 2010 Feb; 120(1):1-7. PubMed ID: 19760503 [TBL] [Abstract][Full Text] [Related]
35. Comparison of dual-colour chromogenic in-situ hybridization and fluorescence in-situ hybridization in the assessment of HER2 gene amplification in breast carcinoma. Conlon S; Colgan A; Allen D; O'Grady A; Kay EW Histopathology; 2011 Jan; 58(2):319-21. PubMed ID: 21323957 [No Abstract] [Full Text] [Related]
36. Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer. Koh YW; Lee HJ; Lee JW; Kang J; Gong G Mod Pathol; 2011 Jun; 24(6):794-800. PubMed ID: 21317877 [TBL] [Abstract][Full Text] [Related]
37. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hicks DG; Tubbs RR Hum Pathol; 2005 Mar; 36(3):250-61. PubMed ID: 15791569 [TBL] [Abstract][Full Text] [Related]
38. Comparison of HER2 status determination methods in HER2 (2+) patients: Manual fluorescent in situ hybridization (FISH) vs. dual silver enhanced in situ hybridization (SISH). Pehlivanoglu B; Serin G; Yeniay L; Zekioglu O; Gokmen E; Ozdemir N Ann Diagn Pathol; 2017 Dec; 31():36-40. PubMed ID: 29146056 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of the HER2 amplification status in oesophageal adenocarcinoma by conventional and automated FISH: a tissue microarray study. Prins MJ; Ruurda JP; van Diest PJ; van Hillegersberg R; ten Kate FJ J Clin Pathol; 2014 Jan; 67(1):26-32. PubMed ID: 24043715 [TBL] [Abstract][Full Text] [Related]
40. Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer. Mansfield AS; Sukov WR; Eckel-Passow JE; Sakai Y; Walsh FJ; Lonzo M; Wiktor AE; Dogan A; Jenkins RB Am J Clin Pathol; 2013 Feb; 139(2):144-50. PubMed ID: 23355198 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]